Shiro Nakahara
Associate professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Shiro Nakahara is an Associate Professor at Dokkyo Medical University Saitama Medical Center in Japan. His research focuses on cardiac electrophysiology, including topics such as atrial fibrillation ablation procedures, the efficacy of different ablation systems, and the utility of advanced imaging technologies in cardiac interventions. Recent publications highlight his contributions to understanding atrioventricular nodal reentrant tachycardia and the application of innovative techniques in managing cardiac conditions.
Articles (19)
Background Atrial fibrillation (AF) prevalence has increased with Japan's aging population. Data on cryoballoon ablation (CBA) for persistent AF (PsAF) in Japan is limited. This study reports CBA clinical outcomes in PsAF patients in Japan from the prospective Cryo Global Registry. Methods Data was analyzed from 60 Japanese centers with 1226 PsAF patients that underwent CBA. The primary endpoints were serious adverse events and freedom from atrial arrhythmia (AA) recurrence, at 12 months. The effect of ablation strategy (pulmonary vein isolation [PVI] or PVI with additional ablations [PVI+]) was evaluated. Quality‐of‐life (QoL) was measured by EQ‐5D‐3L questionnaire. Results The patient mean age was 68 ± 10 years and 29.0% were female. The overall 12‐months Kaplan–Meier (KM) estimate for freedom from AA recurrence was 84.4% (95% CI: 82.2%–86.3%). Among PVI+ patients, 33.0% received cavotricuspid isthmus (CTI) and 34.6% received non‐CTI ablation (majority being left‐atrial roofline [27.2%]). The 12‐months KM estimate for freedom from AA recurrence was higher for PVI+ subgroup (86.6% [CI: 83.6%–89.1%]) than PVI subgroup (82.0% [CI: 78.6%–84.9%]) (HR adj = 1.40, p = 0.025). Twenty‐two serious adverse events were reported in 1.6% patients. At 12 months, compared to baseline, QoL improved with a mean summary‐index score difference of 0.03 ± 0.16 ( p < 0.001) and a mean EQ visual analogue scale score difference of 7.9 ± 18.5 ( p < 0.001). Conclusion This study showed CBA is safe and effective for PsAF treatment in real‐world use in Japan. Trial Registration Cryo Global Registry, ClinicalTrials.gov ID NCT02752737
Year:
2026
Notably, most ventricular tachycardia (VT) episodes in patients with VT attributable to structural heart disease are not hemodynamically tolerated. Therefore, techniques for substrate mapping during stable intrinsic or paced rhythm have been developed that eliminate the need to induce VT. Moreover, advances in catheter technology, enabling high-density multi-electrode mapping of abnormal electrograms, have improved the ability of electrophysiologists to identify the substrate responsible for scar-related VT. In addition to the conventional identification of late potentials and local abnormal ventricular activity (LAVA), several substrate imaging approaches have been developed, including the identification of sites of conduction slowing via isochronal late activation mapping and the modification of wavefronts by changing the pacing site. Further, a new near-field algorithm provides a degree of objectivity to the previously subjective annotations of local potential timing. Additionally, changes in the substrate within the scar, specifically the induction of a line of block and subsequent alteration of a LAVA by decremental conduction, can identify functional abnormal ventricular activity that contributes to the development and maintenance of VT and can further improve the accuracy of substrate mapping. Novel cardiac magnetic resonance imaging and computed tomography analyses, facilitated by specialized software, also provide information for non-invasive estimation of the VT isthmus location. Therefore, continued clinical implementation of these techniques and technologies has the potential to improve safety, reduce the complexity, and expand the number of patients who can safely undergo VT ablation.
Year:
2026
Year:
2026
Background The efficacy and safety of tailored pulmonary vein isolation (PVI) guided by either left atrial wall thickness (LAWT) or bipolar voltage remain unclear. Objective The aim of this prospective study was to evaluate the efficacy and safety of each ablation strategy. Methods We conducted a prospective analysis of 97 patients with non‐valvular atrial fibrillation (AF) who underwent an initial RF catheter ablation procedure known as an extensive encircling PVI. Fifty patients underwent PVI using a wall thickness (WT)‐guided approach using ADAS 3D software and 47 patients using a voltage‐guided approach. In each strategy, high‐power short‐duration (HPSD) ablation was applied to regions with increased LAWT or elevated bipolar voltage, respectively, while very high‐power short‐duration (vHPSD) ablation was delivered to the remaining regions. Results The first‐pass PVI rate tended to be higher in the WT‐guided group compared to the Voltage‐guided group (43 [86%] vs. 34 [72%], p = 0.09), and the incidence of acute PV reconnection (APVR) tended to be lower (5 [10%] vs. 11 [23%], p = 0.07). The proportion of patients with PV gaps (defined as the combined occurrence of first‐pass failure and/or APVR) was significantly lower in the WT‐guided group (10 [20%] vs. 18 [38%], p = 0.04). The multivariable‐adjusted analysis demonstrated that WT‐guided ablation was significantly more effective than Voltage‐guided ablation in preventing PV gaps. Both ablation strategies were performed without any procedural complications. Conclusions WT‐guided ablation was associated with a significantly lower incidence of PV gaps than a conventional bipolar voltage‐guided strategy.
Year:
2025
Background High‐power short‐duration (HPSD) ablation is an established therapy for pulmonary vein (PV) isolation (PVI) in atrial fibrillation (AF), aiming to form efficient transmural lesions. Very HPSD (vHPSD) can further shorten ablation time but may increase the risk of acute PVI failure compared with HPSD. A combined HPSD and vHPSD strategy (90 W/50 W combination workflow) potentially balances efficiency and durability, though its clinical feasibility remains unknown. Therefore, this multicenter registry evaluated the acute and long‐term efficacy of a 90 W/50 W combination workflow for PVI in patients with paroxysmal AF. Methods In this prospective study, a total of 101 consecutive patients with paroxysmal AF underwent PVI using radiofrequency ablation with a 90 W/50 W combination workflow. We evaluated acute outcomes, including first‐pass isolation and acute PV reconnection, and monitored atrial tachyarrhythmia recurrences over 12 months. Results Median PVI procedure time was 35 min, with total procedure time at 105 min. First‐pass PVI was achieved in 58.4% of patients, including 74.3% in the right PV and 72.3% in the left PV. Acute PV reconnection occurred in 31.7% (32/101). In multivariate analysis, carina sites independently predicted acute PVI failure in both HPSD and vHPSD groups, while contact force also predicted failure in the HPSD group. After 1 year, 89.9% of patients remained free from documented atrial tachyarrhythmias. Conclusion The 90 W/50 W combination workflow did not notably shorten procedure time or enhance first‐pass success. More standardized strategies, particularly in carina segments with higher contact force and ablation index under HPSD, may be required to ensure optimal lesion durability and favorable outcomes.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Background Despite the positive impact of implantable cardioverter defibrillators (ICDs) and wearable cardioverter defibrillators (WCDs) on prognosis, their implantation is often withheld especially in Japanese heart failure patients with reduced left ventricular ejection fraction (HFrEF) who have not experienced ventricular tachycardia (VT) or ventricular fibrillation (VF) for uncertain reasons. Recent advancements in heart failure (HF) medications have significantly improved the prognosis for HFrEF. Given this context, a critical reassessment of the treatment and prognosis of ICDs and WCDs is essential, as it has the potential to reshape awareness and treatment strategies for these patients. Methods We are initiating a prospective multicenter observational study for HFrEF patients eligible for ICD in primary and secondary prevention, and WCD, regardless of device use, including all consenting patients. Study subjects are to be enrolled from 31 participant hospitals located throughout Japan from April 1, 2023, to December 31, 2024, and each will be followed up for 1 year or more. The planned sample size is 651 cases. The primary endpoint is the rate of cardiac implantable electronic device implementation. Other endpoints include the incidence of VT/VF and sudden death, all‐cause mortality, and HF hospitalization, other events. We will collect clinical background information plus each patient's symptoms, Clinical Frailty Scale score, laboratory test results, echocardiographic and electrocardiographic parameters, and serial changes will also be secondary endpoints. Results Not applicable. Conclusion This study offers invaluable insights into understanding the role of ICD/WCD in Japanese HF patients in the new era of HF medication.
Year:
2024
Year:
2023
Year:
2023
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Collaborators (7)
Ritsushi Kato
-
Hidehira Fukaya
Junior Associate Professor
Kitasato University School of Medicine
Takeshi Kato
Kanazawa University
Atsuhiko Yagishita
Tokai University
Masahide Harada
Associate Professor
Fujita Health University
Morio Shoda
Professor
Tokyo Women's Medical University
Yasuo Okumura
-
Make your next move.
Prepare your application
Review drafts before you send them.